You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Drug Price Trends for NDC 00115-1555


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00115-1555

Drug Name NDC Price/Unit ($) Unit Date
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.26470 EACH 2025-05-21
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.25747 EACH 2025-04-23
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.28820 EACH 2025-03-19
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.31372 EACH 2025-02-19
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.32056 EACH 2025-01-22
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.36118 EACH 2024-12-18
FENOFIBRIC ACID DR 135 MG CAP 00115-1555-10 0.28214 EACH 2024-11-20
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00115-1555

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 73.87 0.82078 2023-01-01 - 2027-06-30 FSS
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 12.86 0.14289 2024-01-01 - 2027-06-30 Big4
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 73.82 0.82022 2024-01-01 - 2027-06-30 FSS
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 12.39 0.13767 2022-09-27 - 2027-06-30 Big4
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 73.87 0.82078 2022-09-27 - 2027-06-30 FSS
FENOFIBRIC ACID 135MG CAP,EC Amneal Pharmaceuticals of New York, LLC 00115-1555-10 90 14.87 0.16522 2023-01-01 - 2027-06-30 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for the Pharmaceutical Industry: Implications for NDC 0115-1741 and Similar Drugs

Introduction

The pharmaceutical industry is a complex and dynamic sector, influenced by various factors including regulatory changes, technological advancements, and economic trends. This article will provide a comprehensive market analysis and price projections relevant to drugs like Methylphenidate Hydrochloride (NDC 0115-1741), highlighting key trends and predictions for the industry.

Current Market Trends

Drug Price Inflation

Drug price inflation is a significant concern in the pharmaceutical industry. According to Vizient, Inc., the overall drug price inflation rate for pharmaceuticals in 2025 is projected to be 3.81%[2]. This inflation is partly driven by the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies.

Biopharma and Biotech Growth

The biopharma and biotech sectors are experiencing rapid growth, with the biopharma market size estimated to be over $400 billion in 2024 and a projected compound annual growth rate (CAGR) of 7.56% between 2024 and 2029. The biotech sector is also growing, with a market size of nearly $500 billion in 2020 and a CAGR of 9.4% between 2021 and 2027[3].

Global Pricing Disparities

U.S. vs. International Prices

The prices of pharmaceuticals in the U.S. are significantly higher compared to other regions. According to an ASPE issue brief, the average price per unit in the U.S. was 5.5 times as high as in the OECD (excluding the U.S.) and 7.7 times as high as the rest of the world (excluding the U.S.) by 2022[4].

Regulatory Landscape

Evolving Clinical Trial Designs

Clinical trial designs are becoming more innovative to promote efficiency and reduce the exposure of patients to ineffective therapies. In 2025, there is a predicted shift towards more accelerated and adaptive clinical trial designs, which could impact the development and approval timelines of drugs like Methylphenidate Hydrochloride[3].

Regulatory Frameworks

Regulatory frameworks are evolving to keep pace with innovation. This includes more flexible and patient-centered approaches in clinical trials, which can influence the approval and pricing of new and existing drugs[3].

Technological Advancements

Precision Medicine and AI/ML

The use of precision medicine and AI/ML technologies is on the rise. These technologies can enhance drug development, personalize treatment plans, and improve the efficiency of clinical trials. This trend is expected to continue in 2025, potentially impacting the development and pricing of drugs[3].

Market Size and Revenue Trends

Small Molecule vs. Biologic Drugs

There are stark differences in market trends between small molecule drugs and biologic products. In the U.S., sales revenues for small molecule drugs grew by 4% between 2017 and 2022, while biologic products saw a significant growth of 61% during the same period[4].

Price Projections for NDC 0115-1741

General Trends

Given the overall drug price inflation rate of 3.81% projected for 2025, it is likely that the price of Methylphenidate Hydrochloride (NDC 0115-1741) will also increase. However, the extent of this increase will depend on various factors including the drug's market position, competition, and any changes in its approved indications.

Impact of Regulatory and Technological Changes

The evolving regulatory landscape and technological advancements could influence the pricing strategy for this drug. For instance, if new indications are approved or if the drug becomes part of a precision medicine approach, its price could be adjusted accordingly.

Case Study: Methylphenidate Hydrochloride

Current Status

Methylphenidate Hydrochloride is an extended-release oral capsule used primarily for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is classified as a Central Nervous System Stimulant and is distributed by Amneal Pharmaceuticals of New York LLC[1].

Market Position

As a generic drug, Methylphenidate Hydrochloride faces competition from other generic and brand-name versions of methylphenidate. The pricing of this drug is influenced by market competition, regulatory approvals, and the overall demand for ADHD treatments.

Key Takeaways

  • Drug Price Inflation: The pharmaceutical industry is expected to see a 3.81% price inflation rate in 2025.
  • Biopharma and Biotech Growth: These sectors are experiencing significant growth, driven by technological advancements and evolving regulatory frameworks.
  • Global Pricing Disparities: U.S. drug prices are substantially higher than those in other regions.
  • Regulatory and Technological Changes: Innovations in clinical trial designs, precision medicine, and AI/ML technologies will continue to shape the industry.
  • Market Trends: Different trends are observed between small molecule drugs and biologic products, with biologics showing higher growth rates.

FAQs

1. What is the projected drug price inflation rate for 2025? The projected drug price inflation rate for 2025 is 3.81% according to Vizient, Inc.[2].

2. How is the biopharma market expected to grow? The biopharma market is expected to grow with a CAGR of 7.56% between 2024 and 2029, driven by technological advancements and evolving regulatory frameworks[3].

3. Why are U.S. drug prices higher than international prices? U.S. drug prices are higher due to a combination of higher prices for the same drugs and a drug mix that skews towards more expensive drug compounds[4].

4. How are clinical trial designs changing? Clinical trial designs are shifting towards more innovative and adaptive approaches to promote efficiency and reduce patient exposure to ineffective therapies[3].

5. What role do precision medicine and AI/ML play in drug development? Precision medicine and AI/ML technologies are enhancing drug development by personalizing treatment plans and improving the efficiency of clinical trials[3].

Sources

  1. FDA Report: NDC 0115-1741 Oral Capsule, Extended Release Methylphenidate Hydrochloride.
  2. Vizient Inc.: Vizient projects drug price inflation at 3.81%.
  3. TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
  4. ASPE Issue Brief: International Market Size and Prices.
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.